In the validation cohorts, mean plasmatic ADAMTS-13 concentration (Figure 6) was not significantly different in plasma from FD patients compared to healthy controls, although we could appreciate from mean values (513.06 ± 37.54 ng/mL in controls and 672.14 ± 51.88 ng/mL in FD patients: in naïve 690.21 ± 65.40 ng/mL and in ERT-treated 658.34 ± 70.24 ng/mL) that the concentration of ADAMTS-13 tended to be higher in both naïve and ERT-treated patient cohorts. This evidence concerns the gene ADAMTS13 and Fabry disease.